Article citationsMore >>

Ballantyne CM, Banach M, Mancini GBJ, NE, JC, X, LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study, Atherosclerosis, 277:195-203, 2018.

has been cited by the following article:

Article

Prescription of Bempedoic Acid By General Practitioners in Dyslipidemic Patients Not At Target in Primary Prevention

1Centre of Diabetes and Metabolic Diseases, University of Pavia, and IRCCS Policlinico San Matteo Foundation, PAVIA, Italy

2Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy;Department of Internal Medicine and Therapeutics, University of Pavia, PAVIA, Italy

3Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy

4Department of Internal Medicine and Therapeutics, University of Pavia, PAVIA, Italy

5General Practictioner - ASST Pavia, PAVIA, Italy


American Journal of Medical Sciences and Medicine. 2025, Vol. 13 No. 4, 64-69
DOI: 10.12691/ajmsm-13-4-3
Copyright © 2025 Science and Education Publishing

Cite this paper:
Giuseppe Derosa, Pamela Maffioli, Angela D’Angelo, Federico Naj, Riccardo Naj, Giorgio Rubino, Matteo Bressani, Luca Bellazzi, Mario Giacometti, Fortunato Capaccioni, Alessandro Rubino. Prescription of Bempedoic Acid By General Practitioners in Dyslipidemic Patients Not At Target in Primary Prevention. American Journal of Medical Sciences and Medicine. 2025; 13(4):64-69. doi: 10.12691/ajmsm-13-4-3.

Correspondence to: Giuseppe  Derosa, Centre of Diabetes and Metabolic Diseases, University of Pavia, and IRCCS Policlinico San Matteo Foundation, PAVIA, Italy. Email: giuseppe.derosa@unipv.it

Abstract

Background Dyslipidemia is a major risk factor for cardiovascular disease, and achieving LDL-C targets is crucial in primary prevention. However, many patients remain above target due to statin intolerance or inadequate response to therapy. This study evaluates the effectiveness of bempedoic acid, alone or with ezetimibe, in achieving LDL-C goals in a real-world primary prevention population managed by general practitioners (GPs). Methods A total of 254 dyslipidemic patients at moderate cardiovascular risk (LDL-C target: 100 mg/dl) were enrolled. 87.8% were statin-tolerant, while 10.2% were statin-intolerant. Patients received bempedoic acid alone or in combination with ezetimibe for nine months, and changes in lipid profile, glycemic parameters, and safety markers were assessed. Results LDL-C levels significantly decreased from 144.9 ± 27.3 mg/dl to 93.2 ± 11.6 mg/dl (p<0.01), successfully bringing all patients within the target of 100 mg/dl. Triglycerides (p= 0.71) did not decline significantly and TC (p<0.01) declined significantly, while FPG remained stable (−2.2%; p= 0.77). Notably, 61.4% of patients were prediabetic, making the neutral metabolic impact of bempedoic acid particularly relevant. The treatment was well tolerated, with no significant hepatic or muscular adverse effects. Conclusions Bempedoic acid, alone or with ezetimibe, effectively lowers LDL-C to guideline-recommended targets in primary prevention patients, including those with statin intolerance. The study highlights the key role of general practitioners in optimizing lipid management, reinforcing the importance of early and targeted interventions to reduce cardiovascular risk in real-world primary care settings.

Keywords